FI20075258A0 - Menetelmä integriiniinhibiittorirespondereiden seulomiseksi - Google Patents
Menetelmä integriiniinhibiittorirespondereiden seulomiseksiInfo
- Publication number
- FI20075258A0 FI20075258A0 FI20075258A FI20075258A FI20075258A0 FI 20075258 A0 FI20075258 A0 FI 20075258A0 FI 20075258 A FI20075258 A FI 20075258A FI 20075258 A FI20075258 A FI 20075258A FI 20075258 A0 FI20075258 A0 FI 20075258A0
- Authority
- FI
- Finland
- Prior art keywords
- responders
- selling
- procedure
- integrin inhibitors
- blockade
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20075258A FI20075258A0 (fi) | 2007-04-17 | 2007-04-17 | Menetelmä integriiniinhibiittorirespondereiden seulomiseksi |
AU2008237804A AU2008237804A1 (en) | 2007-04-17 | 2008-04-16 | A method for selecting responders to blockade of integrin receptors |
EP08736844A EP2140029A2 (en) | 2007-04-17 | 2008-04-16 | A method for selecting responders to blockade of integrin receptors |
PCT/FI2008/050195 WO2008125738A2 (en) | 2007-04-17 | 2008-04-16 | A method for selecting responders to blockade of integrin receptors |
US12/596,292 US20120052057A9 (en) | 2007-04-17 | 2008-04-16 | method for selecting responders to blockade of integrin receptors |
CA002683312A CA2683312A1 (en) | 2007-04-17 | 2008-04-16 | A method for selecting responders to blockade of integrin receptors |
JP2010503536A JP2010527233A (ja) | 2007-04-17 | 2008-04-16 | インテグリン受容体の遮断に対する反応者の選別方法 |
NZ580235A NZ580235A (en) | 2007-04-17 | 2008-04-16 | A method for selecting responders to blockade of integrin receptors |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20075258A FI20075258A0 (fi) | 2007-04-17 | 2007-04-17 | Menetelmä integriiniinhibiittorirespondereiden seulomiseksi |
Publications (1)
Publication Number | Publication Date |
---|---|
FI20075258A0 true FI20075258A0 (fi) | 2007-04-17 |
Family
ID=38009911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20075258A FI20075258A0 (fi) | 2007-04-17 | 2007-04-17 | Menetelmä integriiniinhibiittorirespondereiden seulomiseksi |
Country Status (8)
Country | Link |
---|---|
US (1) | US20120052057A9 (fi) |
EP (1) | EP2140029A2 (fi) |
JP (1) | JP2010527233A (fi) |
AU (1) | AU2008237804A1 (fi) |
CA (1) | CA2683312A1 (fi) |
FI (1) | FI20075258A0 (fi) |
NZ (1) | NZ580235A (fi) |
WO (1) | WO2008125738A2 (fi) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3023497A1 (en) * | 2005-11-18 | 2016-05-25 | Glenmark Pharmaceuticals S.A. | Anti-alpha2 integrin antibodies and their uses |
WO2013155686A1 (zh) * | 2012-04-18 | 2013-10-24 | Wang Lemin | 整合素β亚基在诊断静脉血栓栓塞中的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6096707A (en) * | 1997-07-11 | 2000-08-01 | Biotie Therapies Ltd. | Integrin binding peptide and use thereof |
JP2004141112A (ja) * | 2002-10-28 | 2004-05-20 | Pharma Design Inc | 2型糖尿病患者における動脈硬化に対する易罹患性の判定方法 |
FI20055498A0 (fi) * | 2005-09-16 | 2005-09-16 | Biotie Therapies Corp | Sulfonamidijohdannaisia |
-
2007
- 2007-04-17 FI FI20075258A patent/FI20075258A0/fi unknown
-
2008
- 2008-04-16 AU AU2008237804A patent/AU2008237804A1/en not_active Abandoned
- 2008-04-16 CA CA002683312A patent/CA2683312A1/en not_active Abandoned
- 2008-04-16 WO PCT/FI2008/050195 patent/WO2008125738A2/en active Application Filing
- 2008-04-16 US US12/596,292 patent/US20120052057A9/en not_active Abandoned
- 2008-04-16 EP EP08736844A patent/EP2140029A2/en not_active Withdrawn
- 2008-04-16 NZ NZ580235A patent/NZ580235A/en unknown
- 2008-04-16 JP JP2010503536A patent/JP2010527233A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2683312A1 (en) | 2008-10-23 |
WO2008125738A3 (en) | 2008-12-11 |
NZ580235A (en) | 2011-03-31 |
WO2008125738A2 (en) | 2008-10-23 |
AU2008237804A1 (en) | 2008-10-23 |
US20110150859A1 (en) | 2011-06-23 |
EP2140029A2 (en) | 2010-01-06 |
WO2008125738A8 (en) | 2009-07-30 |
US20120052057A9 (en) | 2012-03-01 |
JP2010527233A (ja) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124307T1 (el) | Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων | |
CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
CY1120961T1 (el) | Δοσολογικες μορφες απο του στοματος που περιλαμβανουν αντιαιμοπεταλιακο παραγοντα και αναστολεα οξεος | |
CY1117678T1 (el) | Ενωσεις αναστολεων μεταλλοενζυμου | |
CY1123552T1 (el) | Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas | |
LTPA2016030I1 (lt) | Dauginės mielomos, naudojant kombinuotas terapijas, pagrįstas anti-CS1 antikūnais, gydymo būdai | |
EA200900091A1 (ru) | Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний | |
CY1118125T1 (el) | Αναστολεις ιβατ για τη θεραπεια ηπατικων νοσων | |
MA32934B1 (fr) | Combinaisons inhibitrices hsp90 | |
MX2014000518A (es) | Inhibidores de la tirosina quinasa de bruton. | |
NO20090047L (no) | Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse | |
MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
IN2012DN03012A (fi) | ||
EA200870185A1 (ru) | Комбинации ингибиторов ang2 и vegf | |
ATE534752T1 (de) | Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll) | |
EA201170252A1 (ru) | Амидофеноксиндазолы в качестве ингибиторов c-мет | |
BR112014012590A8 (pt) | Anticorpos anti-cd98 e métodos de uso dos mesmos | |
EA201170227A1 (ru) | Имидазолкарбоксамиды | |
NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
EA201071099A1 (ru) | СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR | |
CY1115437T1 (el) | Υδροξυμεθυλοκυκλοεξυλαμινες | |
EA201492284A1 (ru) | Применение маркеров в диагностике и лечении рака предстательной железы | |
CY1116216T1 (el) | Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου | |
BRPI0822129A2 (pt) | Inibidores de aldh-2c no tratamento de vício. | |
EA200970816A1 (ru) | Новая лекарственная форма |